A Breakthrough in the Challenges of Tuberculosis Diagnosis: Lateral Flow Urine Lipoarabinomannan (LAM) Assay for the Diagnosis of Active Tuberculosis in a Subset of Human Immuno Deficiency Virus (HIV) Patients at Hawassa University Comprehensive Specialized Hospital, Hawassa, Ethiopia.
Worku Ketema BededaKindie WoubishetAgete Tadewos HirigoSelamawit GutemaKefyalew Taye GariMulugeta Sitot ShibeshiNegash TagessePublished in: International medical case reports journal (2022)
Ending the suffering of HIV patients necessitates lobbying for more accurate tuberculosis diagnosis. The urine Lipoarabinomannan (LAM) assay will address the shortcomings of traditional sputum-based diagnostic tests including sputum Acid Fast Bacilli (AFB) and Gene X-pert, making it a credible alternative for diagnosing tuberculosis in people with HIV. The results of this case series demonstrated that TB LAM is a milestone for the difficulties in TB diagnosis in HIV patients. As of now, the national guideline only suggests urine LAM for HIV patients who fulfill the set criteria. We recommend the stakeholders to increase the availability, and extrapolate the recommendation to other populations including non-HIV patients.
Keyphrases
- antiretroviral therapy
- hiv aids
- mycobacterium tuberculosis
- hiv positive
- hiv infected
- human immunodeficiency virus
- end stage renal disease
- hiv testing
- hepatitis c virus
- ejection fraction
- men who have sex with men
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- cystic fibrosis
- endothelial cells
- high throughput
- emergency department
- south africa
- gene expression
- patient reported outcomes
- palliative care
- mass spectrometry
- high resolution
- acute care